Overview
Electroconvulsive therapy and ketamine represent two of the most effective interventions for treatment-resistant depression. ECT, introduced in the 1930s, has the longest track record and remains the gold standard for severe, medication-refractory depression. Ketamine, repurposed from anesthesia in the 2000s, has emerged as a less invasive alternative with comparable efficacy in many populations.
The 2023 ELEKT-D trial, a landmark multi-site randomized study, directly compared IV ketamine to ECT in patients with non-psychotic treatment-resistant depression and found ketamine to be non-inferior to ECT in reducing depressive symptoms.
Mechanism
| Aspect | Ketamine | ECT |
|---|---|---|
| Mechanism | NMDA receptor blockade, glutamate surge | Controlled seizure inducing neurochemical cascade |
| Anesthesia required | No (for subanesthetic doses) | Yes (general anesthesia each session) |
| Neuroplasticity | BDNF-mTOR pathway activation | BDNF increase, hippocampal neurogenesis |
| Memory effects | Minimal, transient | Can cause retrograde and anterograde amnesia |
ECT works by inducing a brief, controlled generalized seizure under general anesthesia. The exact antidepressant mechanism is not fully understood but involves widespread neurochemical changes, increased BDNF, hippocampal neurogenesis, and alterations in neural network connectivity.
Efficacy
| Metric | Ketamine | ECT |
|---|---|---|
| Response rate (TRD) | 50 to 70 percent | 60 to 80 percent |
| Remission rate | 30 to 40 percent | 50 to 65 percent |
| Onset | Hours | 2 to 3 weeks (after multiple sessions) |
| Duration of effect | Days to weeks per treatment | Weeks to months per course |
| Effectiveness for psychotic depression | Limited data | Superior (70 to 90 percent response) |
ECT achieves higher remission rates overall, particularly for psychotic depression where response rates reach 70 to 90 percent. Ketamine's advantage is speed — antidepressant effects begin within hours versus weeks for ECT. The ELEKT-D trial found comparable efficacy in non-psychotic TRD.
Cognitive Side Effects
The most significant distinguishing factor is cognitive impact. ECT is associated with retrograde amnesia (difficulty recalling memories from before treatment) and anterograde amnesia (difficulty forming new memories during the treatment period). While usually temporary, some patients report persistent memory difficulties.
Ketamine produces transient dissociation and cognitive impairment during administration that resolves within 1 to 2 hours. Long-term cognitive effects at therapeutic doses have not been demonstrated in clinical studies.
Treatment Protocol
| Factor | Ketamine | ECT |
|---|---|---|
| Sessions per course | 6 over 2 to 3 weeks | 6 to 12 over 3 to 4 weeks |
| Session duration | 1 to 2 hours total | 30 to 60 minutes (plus recovery) |
| Anesthesia | None required | General anesthesia each session |
| Recovery time | 1 to 2 hours, no driving day-of | Several hours, no driving day-of |
| Setting | Clinic or supervised at-home | Hospital or specialized center |
Patient Acceptance
Ketamine has significantly higher patient acceptance than ECT. The stigma associated with ECT, concerns about memory loss, and the requirement for repeated general anesthesia create barriers to treatment. Ketamine can be framed as a medication infusion rather than a procedure, which many patients find more acceptable.
Cost
ECT sessions typically cost $1,000 to $2,500 each but are more frequently covered by insurance than ketamine, given ECT's established evidence base and APA guideline endorsement. Ketamine infusions at $400 to $800 per session are usually out-of-pocket. See our ketamine therapy cost guide for full pricing details.
References
- Anand et al. — ELEKT-D Trial — Ketamine versus ECT for nonpsychotic treatment-resistant major depression
- UK ECT Review Group — ECT Meta-Analysis — Efficacy of electroconvulsive therapy in depressive illness
- Semkovska and McLoughlin — ECT Cognitive Effects — Objective cognitive performance and ECT
- NIMH — Brain Stimulation Therapies — NIMH brain stimulation information
Verdict
ECT remains the most effective treatment for severe, treatment-resistant depression, with remission rates of 50 to 65 percent. Ketamine offers comparable response rates with faster onset, fewer cognitive side effects, and greater patient acceptance. The landmark ELEKT-D trial (2023) found IV ketamine non-inferior to ECT for non-psychotic TRD, while ECT may retain advantages for psychotic depression and catatonia.
Share